Clinical updates, including trial initiations, enrollment status and data readouts and publications: Hyperfine, Myriad Genetics, Tempus AI.

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Bluejay Diagnostics, Burl Concepts, Imagine Devices, Neotech, Robocath, Siemens Healthineers.

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abanza, Outset Medical, Spine Innovation.

New hires and promotions in the med-tech industry, including: Daiichi Sankyo, Nxera Pharma.

Biopharmas in Asia-Pacific raising money in public or private financings: Corxel, Harbour Biomed, Sprice Biosciences, Vincentage.

Biopharma happenings in Asia-Pacific including deals and partnerships, grants, preclinical data and other news in brief: Altogen, Ellipses Pharma, GSK, Hygtia Therapeutics, Innolake Biopharm, Insilico Medicine, Kuva, Lisata Therapeutics, Orthocell, Pfizer, Qilu Pharmaceutical, Shionogi, Tesaro, Viiv Healthcare.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Nasus, Nxera.

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Akeso, Daiichi Sankyo, GKS, Ionis, Iregene, Mesoblast, Nanoscope, Sun Pharmaceutical.

The top 10 med-tech stock gainers and losers for the week.

Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: GSK, Okyo, Sun.